Find the latest updates on our scientific progress on multiple fronts
Jul 27, 2023
ARIScience named a finalist in the US government's global AI challenge to reliably predict at risk pediatric COVID-19 patients
The paper resulting from the "New COVID-19 Variants - Post Challenge Analysis" challenge was accepted and will soon be published by the Cambridge University Press Journal of Clinical and Translational Science
Apr 7, 2023
Crystallization of an essential DENV2 protein in the presence of one of ARIScience's lead candidates
ARIScience continues engage in groundbreaking work on Dengue protein interruption
Nov 17, 2022
ARIScience furthers research on COVID-19's impact on diabetic patients
ARIScience's research on COVID-19's impact on diabetic patients reveals statistically significant associations between metformin use and less severe outcomes from COVID-19 compared to SU use, but not compared to DPP4i use.
Jul 31, 2022
ARIScience Collaboration on SARS-CoV-2 Research
ARIScience and University of North Dakota signed a research collaboration agreement on the use of the UND Computational Research Center’s (UND CRC) high performance computing (HPC) system to further ARIScience’s SARS-CoV-2 protein interruption research.
Feb 20, 2022
M2D2 selects ARIScience as a "Runner Up"
M2D2 selects ARIScience as a "Runner Up" in their 2022 challenge focused on identifying and rewarding disruptive companies in the medical technology and biotechnology industries.
Jul 31, 2021
Two-step Method Identifies Known Drugs Likely to Reduce Chance of Death from COVID-19
Bridges helps identify meds for other conditions that associate with lower death rates in COVID-19 patients
May 27, 2021
SARSCOV2/COVID19 protein interruption search with existing active compounds using quasi-quantum simulation
COVID-19 HPC Consortium and XSEDE provides access to multiple super-computing centers to speed along ARI's breakthrough COVID-19 research.
May 6, 2021
CTSA-CLIC writes about ARIScience's SARS-CoV-2 drug repositioning research
EHR data from the N3C Data Enclave were used to produce a recent preprint published in medRxiv authored by ARIScience's Joy Alamgir, et al.
Apr 6, 2021
Massachusetts Startup Uses Supercomputing to Identify Four Promising COVID Therapeutics
Oliver Peckham of HPCWire writes about ARIScience's COVID-19 research results - on the four re-positioned candidate drugs - here.
Apr 6, 2021
Drug repositioning candidates identified using in-silico quasi-quantum molecular simulation demonstrate reduced COVID-19 mortality in 1.5M patient records.
From early May 2020 we dove right into finding a solution for COVID-19 crisis using our cutting edge quasi-quantum analysis and simulation platform. Our detailed findings are here.
Mar 31, 2021
Biotech firm identifies four drugs that could be used against COVID-19
The ongoing rollout of vaccines against COVID-19 has sparked hope of life soon getting back to normal. But vaccines are not the only piece of the pandemic’s jigsaw puzzle. We also need new drugs to fight the disease.
Oct 3, 2020
Scope of Real-world Data in Drug Repositioning
ARIScience now has access to over 1.5MM detailed de-identified patient records (medications, procedures, diagnoses and much more) for COVID-19 research. A video interview of how we are using this dataset can be found here.
Aug 13, 2020
Checking the Medicine Cabinet to Interrupt COVID-19 at the Molecular Level
In the face of the COVID 19 pandemic, a Massachusetts biotech startup turns to the MGHPCC for HPC resources in its hunt for existing FDA-approved drugs that might be a therapeutic candidate against the novel coronavirus.
Join Our Mission
Join us in revolutionizing the field of drug discovery and improving the lives of patients worldwide. If you are interested in partnering with ARIScience please contact us today to discuss collaboration opportunities.